The T61 human breast cancer xenograft: An experimental model of estrogen therapy of breast cancer

Breast Cancer Research and Treatment

Volumn 39, Issue 1, 1996, Pages 87-92

  Brünner, Nils ^a   Spang Thomsen, Mogens ^b   Cullen, Kevin ^c  

^a FINSEN LABORATORY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Endocrine therapy; Estrogen treatment; IGF I; IGF II; T61 xenograft breast cancer model; Tamoxifen; TGF

Indexed keywords

DIETHYLSTILBESTROL; ESTROGEN; ESTROGEN RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; BREAST DUCT; CANCER TRANSPLANTATION; CARDIOVASCULAR DISEASE; CELL STRAIN MCF 7; CLINICAL TRIAL; DRUG MECHANISM; ENDOMETRIUM CARCINOMA; ESTROGEN THERAPY; FEMALE; HUMAN; HUMAN TISSUE; LIGAND BINDING; MALE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR GROWTH; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0029868225     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806080     Document Type: Article

References (21)

1. Vignon F, Bouton MM, Rochefort H: Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun 146:1502-1508, 1987
2. Jordan VC: Overview from the international conference on lung-term tamoxifen therapy for breast cancer. J Natl Cancer Inst 84:231-234, 1992
3. Palshof T: Adjuvant endocrine therapy in premenopausal and postmenopausal women with breast cancer. A report on the Copenhagen Breast Cancer Trials 1975-1987. Medi-book, Copenhagen, 1988
4. Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR: Diethylstilbestrol: Recommended dosages for different categories of breast cancer patients. JAMA 237: 2079-2085, 1977
5. Matelski H, Greene R, Huberman M, Lokich J, Zipoli T: Randomized trial of estrogen versus tamoxifen therapy for advanced breast cancer. Am J Clin Oncol 8:128-133, 1985
6. Beex L, Pieters G, Smals A, Koenders A, Benraad T, Kloppenberg P: Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rep 65:179-185, 1981
7. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, et al: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304:16-21, 1981
8. Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R: MCF-7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 53:3229-3232, 1993
9. von Schoultz B, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette Å, Stege R: Estrogen therapy and liver function - Metabolic effects of oral and parental administration. Prostate 14:389-395, 1989
10. Aro J, Haapiainen R, Sane T, Rannikko S, Pelkonen R, Alfthan O: Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients. Eur Urol 17:229-235, 1990
11. Henriksson P, Eriksson A, Stege R, Collste L, Pousette Å, von Schoultz B, Carlström K: Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate 13:257-261, 1988
12. Aro J: Cardiovascular and all-causes mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population. Prostate 18:131-137, 1991
13. Ostrowski MJ, Jackson AW: Polyestradiol phosphate: A preliminary evaluation of its effect on breast carcinoma. Cancer Treat Rep 63:1803-1807, 1979
14. Brünner N, Bastert GB, Poulsen HS, Spang-Thomsen M, Engelholm SA, Vindeløv L, Nielsen A, Tommerup N, Elling F: Characterization of the T61 human breast carcinoma established in nude mice. Eur J Cancer 7:833-843, 1985
15. Brünner N, Spang-Thomsen M, Vindeløv L, Nielsen A, Engelholm SA, Svenstrup B: Dose-dependent effect of 17β-estradiol determined by growth curves and flow cytometric DNA analysis of a human breast carcinoma (T61) grown in nude mice. Expl Cell Biol 53:220-232, 1985
16. Brünner N, Spang-Thomsen M, Vindeløv L, Wolff J, Engelholm SA: Effect of tamoxifen on the receptor-positive T61 and the receptor-negative T60 human breast carcinomas grown in nude mice. Eur J Cancer 11:1349-1354, 1985
17. Jiang SY, Jordan VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 84:580-591, 1992
18. Garcia M, Derocq D, Freiss G, Rochefort H: Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci USA 89:11538-11542, 1992
19. Tobin G, Yee D, Brünner N, Rotwein P: A novel human insulin-like growth factor I messenger RNA is expressed in normal and tumor cells. Mol Endocrinol 4:1914-1920, 1990
20. Brünner N, Yee D, Kern FG, Spang-Thomsen M, Lippman ME, Cullen K: Efffect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). Eur J Cancer 4:562-569, 1993
21. Yee D, Cullen KJ, Paik S, Perdue JF, Hampton B, Schwartz A, Lippman ME, Rosen N: Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 48:6691-6696, 1988